26 completed, 6 unknown, 3 recruiting, 2 active not recruiting. 38 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Completed 26, Unknown 6, Recruiting 3, Active not recruiting 2, Terminated 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IN026 in Participants With Refractory Gout IN026 Injection - Refractory Gout | Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 16 | 2026-06-12 | 2026-07-31 |
| A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia NNC4004-0002, Placebo - Healthy Volunteers, Hyperuricemia | Phase 1 | Active not recruiting | Novo Nordisk A/S | 50 | 2024-11-13 | 2026-10-26 |
| A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease IG3018, Placebo matching IG3018 - Hyperuricemia, Hypouricemia, Renal | Phase 1 / Phase 2 | Recruiting | Intelligem Therapeutics Australia Pty Ltd. | 60 | 2024-11-12 | 2026-02-03 |
| PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function SAP-001 - Gout, Hyperuricemia | Phase 1 / Phase 2 | Active not recruiting | Shanton Pharma Pte. Ltd. | 32 | 2024-04-24 | 2024-12-11 |
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo - Gout and Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2024-01-04 | 2024-03-06 |
| Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects SHR4640 - Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 34 | 2023-12-13 | 2024-01-23 |
| Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia Pegylated Recombinant Candida Utilis Uricase for Injection - Gout, Hyperuricemia | Phase 1 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 60 | 2023-11-20 | 2025-05-28 |
| Effect of Tigulixostat on the Pharmacokinetics of Theophylline Tigulixostat, Theophylline - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 24 | 2023-10-31 | 2024-01-03 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects SHR4640 - Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2023-08-07 | 2024-07-11 |
| SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects SAP-001, Placebo - Gout, Hyperuricemia | Phase 1 | Completed | Shanton Pharma Co., Ltd. | 70 | 2023-05-29 | 2024-11-12 |
| A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels PRX-115, Placebo - Gout | Phase 1 | Completed | Protalix | 64 | 2023-03-23 | 2025-02-11 |
| A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine - Asymptomatic Hyperuricemia | Phase 1 | Completed | Shanghai Institute Of Biological Products | 45 | 2022-04-11 | 2023-12-27 |
| Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal, Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state - Hyperuricemia, Gout | Phase 1 | Completed | Allena Pharmaceuticals | 12 | 2022-01-11 | 2023-01-23 |
| Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers Polyglycol lated urate oxidase for injection, Placebo - Hyperuricemia | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 54 | 2021-12-08 | 2022-02-07 |
| Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults LC350189 Tablet, LC350189 Capsule - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 23 | 2021-07-31 | 2022-01-06 |
| Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) ALLN-346, Placebo - Hyperuricemia, Gout | Phase 1 | Completed | Allena Pharmaceuticals | 18 | 2021-04-21 | 2021-07-01 |
| A Safety and Tolerability Study of FCN-207 in Healthy Volunteers Placebo, fasted vs. high-fat meal - Hyperuricemia | Phase 1 | Completed | Fochon Pharmaceuticals, Ltd. | 132 | 2020-11-11 | 2024-08-05 |
| Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers SHR4640 - Primary Gout, Hyperuricemia | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2020-10-01 | 2020-10-14 |
| ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers ALLN-346, Placebo - Hyperuricemia | Phase 1 | Completed | Allena Pharmaceuticals | 24 | 2020-09-02 | 2021-07-23 |
Showing 20 of 38. Sign in to see all of them.
Gout (28) · Metabolic Diseases (1) · Renal Insufficiency, Chronic (1) · Renal hypouricemia (1) · Rheumatic Diseases (1)
Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38) · Arthritis (28) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (28) · Crystal Arthropathies (28) · Genetic Diseases, Inborn (28) · Joint Diseases (28) · Metabolism, Inborn Errors (28) · Musculoskeletal Diseases (28) · Nutritional and Metabolic Diseases (28) · Purine-Pyrimidine Metabolism, Inborn Errors (28) · Metabolic Diseases (27) · Rheumatic Diseases (27) · Chronic Disease (1) · Connective Tissue Diseases (1)
ruzinurad (7) · Injections (2) · Allopurinol (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Dexamethasone (1) · Diphenhydramine (1) · Midazolam (1) · Naproxen (1) · Theophylline (1) · dotinurad (1) · repaglinide (1)
Jiangsu HengRui Medicine Co., Ltd. (7) · LG Chem (6) · Allena Pharmaceuticals (3) · Atom Therapeutics Co., Ltd (2) · EnzymeRx (2) · Shanton Pharma Co., Ltd. (2) · Atridia Pty Ltd. (1) · China Medical University Hospital (1) · Fochon Pharmaceuticals, Ltd. (1) · Intelligem Therapeutics Australia Pty Ltd. (1) · InventisBio Co., Ltd (1) · LG Life Sciences (1) · Novo Nordisk A/S (1) · Pfizer (1) · Protalix (1)
United States (17) · China (13) · Australia (2) · South Korea (2) · Taiwan (2) · New Zealand (1) · United Kingdom (1)
Anthony S Fiorino, MD, PhD (2) · Alan Kivitz, MD (1) · Changgui Li, Doctor (1) · Christine Tosone (1) · Christine Tosone, MS (1) · Christine Tosone, MS, RAC (1) · Danielle Armas, M.D. (1) · Danielle Armas, MD (1) · Huan Zhou (1) · Ji-Young Park, M.D., Ph.D. (1) · John M Hill, MD (1) · Kuo-Chin Huang, MD (1) · Kyung Sang Yu, MD, PhD (1) · Li Li (1)